Effect of ibrutinib treatment on hemolytic anemia and acrocyanosis in cold agglutinin disease/cold agglutinin syndrome

Marit Jalink; Sigbjørn Berentsen; Jorge J. Castillo; Steven P. Treon; Marjan Cruijsen; Bruno Fattizzo; Ramona Cassin; Despina Fotiou; Efstathios Kastritis; Masja de Haas; Liesbeth E. M. Oosten; Henrik Frederiksen; Andrea Patriarca; Shirley D'Sa; Josephine M. I. Vos

doi:https://doi.org/10.1182/blood.2021012039

Effect of ibrutinib treatment on hemolytic anemia and acrocyanosis in cold agglutinin disease/cold agglutinin syndrome

Marit Jalink, Sigbjørn Berentsen, Jorge J. Castillo, Steven P. Treon, Marjan Cruijsen, Bruno Fattizzo, Ramona Cassin, Despina Fotiou, Efstathios Kastritis, Masja de Haas, Liesbeth E. M. Oosten, Henrik Frederiksen, Andrea Patriarca, Shirley D'Sa, Josephine M. I. Vos

Research output: Contribution to journal › Comment/Letter to the editor › Academic

27 Citations (Scopus)

Original language	English
Pages (from-to)	2002-2005
Number of pages	4
Journal	Blood
Volume	138
Issue number	20
DOIs	https://doi.org/10.1182/blood.2021012039
Publication status	Published - 18 Nov 2021

Access to Document

https://doi.org/10.1182/blood.2021012039

Cite this

Jalink, M., Berentsen, S., Castillo, J. J., Treon, S. P., Cruijsen, M., Fattizzo, B., Cassin, R., Fotiou, D., Kastritis, E., de Haas, M., Oosten, L. E. M., Frederiksen, H., Patriarca, A., D'Sa, S., & Vos, J. M. I. (2021). Effect of ibrutinib treatment on hemolytic anemia and acrocyanosis in cold agglutinin disease/cold agglutinin syndrome. Blood, 138(20), 2002-2005. https://doi.org/10.1182/blood.2021012039

@article{51a057f328ce4e32bb7598c4b2527f94,

title = "Effect of ibrutinib treatment on hemolytic anemia and acrocyanosis in cold agglutinin disease/cold agglutinin syndrome",

author = "Marit Jalink and Sigbj{\o}rn Berentsen and Castillo, {Jorge J.} and Treon, {Steven P.} and Marjan Cruijsen and Bruno Fattizzo and Ramona Cassin and Despina Fotiou and Efstathios Kastritis and {de Haas}, Masja and Oosten, {Liesbeth E. M.} and Henrik Frederiksen and Andrea Patriarca and Shirley D'Sa and Vos, {Josephine M. I.}",

note = "Funding Information: Conflict-of-interest disclosure: S.B. received lecture honoraria from Apellis, Bioverativ (a Sanofi-Genzyme company), Janssen-Cilag, and True North Therapeutics and consultancy and advisory board honoraria from Apellis, Bioverativ (a Sanofi-Genzyme company), Momenta Pharmaceuticals, and SOBI. J.J.C. received research funds and/or honoraria from Abbvie, Beigene, Janssen, Pharmacyclics, Roche, and TG Therapeutics. S.P.T. received research support and consulting fees from Janssen and Abbvie/Pharmacyclics and Beigene and research support from BMS, Eli Lilly, and X4. B.F. received consultancy honoraria from Momenta, Alexion, Amgen, and Novartis. E.K. received research support from Amgen and Janssen and honoraria from Amgen, Janssen, Genesis Pharma, Takeda, and Pfizer. H.F. received funding outside this work from Alexion, Gilead, Abbvie, Janssen Pharmaceuticals, and Novartis. A.P. received honoraria from Icyte and Novartis and was on the advisory board for Amgen and Novartis. S.D. received honoraria from Janssen, BeiGene, and Sanofi; research funding from BeiGene and Janssen; was on advisory boards for BeiGene and Sanofi; and was on the speakers bureau for Janssen and BeiGene. J.M.I.V. received travel reimbursement from Celgene and was on the advisory board for Sanofi. All remaining authors declare no competing financial interests.",

year = "2021",

month = nov,

day = "18",

doi = "https://doi.org/10.1182/blood.2021012039",

language = "English",

volume = "138",

pages = "2002--2005",

journal = "Blood",

issn = "0006-4971",

publisher = "American Society of Hematology",

number = "20",

}

Jalink, M, Berentsen, S, Castillo, JJ, Treon, SP, Cruijsen, M, Fattizzo, B, Cassin, R, Fotiou, D, Kastritis, E, de Haas, M, Oosten, LEM, Frederiksen, H, Patriarca, A, D'Sa, S & Vos, JMI 2021, 'Effect of ibrutinib treatment on hemolytic anemia and acrocyanosis in cold agglutinin disease/cold agglutinin syndrome', Blood, vol. 138, no. 20, pp. 2002-2005. https://doi.org/10.1182/blood.2021012039

TY - JOUR

T1 - Effect of ibrutinib treatment on hemolytic anemia and acrocyanosis in cold agglutinin disease/cold agglutinin syndrome

AU - Jalink, Marit

AU - Berentsen, Sigbjørn

AU - Castillo, Jorge J.

AU - Treon, Steven P.

AU - Cruijsen, Marjan

AU - Fattizzo, Bruno

AU - Cassin, Ramona

AU - Fotiou, Despina

AU - Kastritis, Efstathios

AU - de Haas, Masja

AU - Oosten, Liesbeth E. M.

AU - Frederiksen, Henrik

AU - Patriarca, Andrea

AU - D'Sa, Shirley

AU - Vos, Josephine M. I.

N1 - Funding Information: Conflict-of-interest disclosure: S.B. received lecture honoraria from Apellis, Bioverativ (a Sanofi-Genzyme company), Janssen-Cilag, and True North Therapeutics and consultancy and advisory board honoraria from Apellis, Bioverativ (a Sanofi-Genzyme company), Momenta Pharmaceuticals, and SOBI. J.J.C. received research funds and/or honoraria from Abbvie, Beigene, Janssen, Pharmacyclics, Roche, and TG Therapeutics. S.P.T. received research support and consulting fees from Janssen and Abbvie/Pharmacyclics and Beigene and research support from BMS, Eli Lilly, and X4. B.F. received consultancy honoraria from Momenta, Alexion, Amgen, and Novartis. E.K. received research support from Amgen and Janssen and honoraria from Amgen, Janssen, Genesis Pharma, Takeda, and Pfizer. H.F. received funding outside this work from Alexion, Gilead, Abbvie, Janssen Pharmaceuticals, and Novartis. A.P. received honoraria from Icyte and Novartis and was on the advisory board for Amgen and Novartis. S.D. received honoraria from Janssen, BeiGene, and Sanofi; research funding from BeiGene and Janssen; was on advisory boards for BeiGene and Sanofi; and was on the speakers bureau for Janssen and BeiGene. J.M.I.V. received travel reimbursement from Celgene and was on the advisory board for Sanofi. All remaining authors declare no competing financial interests.

PY - 2021/11/18

Y1 - 2021/11/18

UR - http://www.scopus.com/inward/record.url?scp=85116866947&partnerID=8YFLogxK

U2 - https://doi.org/10.1182/blood.2021012039

DO - https://doi.org/10.1182/blood.2021012039

M3 - Comment/Letter to the editor

C2 - 34293088

SN - 0006-4971

VL - 138

SP - 2002

EP - 2005

JO - Blood

JF - Blood

IS - 20

ER -

Effect of ibrutinib treatment on hemolytic anemia and acrocyanosis in cold agglutinin disease/cold agglutinin syndrome

Access to Document

Other files and links

Cite this